

To, Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001

Dear Sir.

Sub: Outcome of the Roard Meeting

BSE Code: 531210

The Meeting of Board of Directors was held on Friday, 30th July, 2021 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

- 1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June, 2021 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Statutory Auditors have carried out "Limited Review" of the above results.

  Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June, 2021.
- 2. The Board approved Director's Report for the year ended 31st March, 2021.
- 3. The Board also approved Management Discussion Report, Corporate Governance Report, CEO's certification & other documents for the year ended 31st March, 2021.
- 4. The Board took note of Secretarial Audit Report issued by M/s. Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2021.
- 5. The Board discussed and finalized the date, time and mode of 35th Annual General Meeting of the Company on Thursday, 30th September, 2021 at 2.30 p.m. through video conference or other audio-visuals means and also approved the draft notice of forthcoming Annual General Meeting of the Company.
- 6. The Board also approved and finalized that the Register of Members will remain closed for the purpose of 35th Annual General Meeting of the Company from 23<sup>rd</sup> September, 2021 to 30<sup>th</sup> September, 2021(both days inclusive). Notice relating to Book Closure is enclosed separately.
- 7. Further pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed 23<sup>rd</sup> day of September, 2021 as the Cut-Off date for the purpose of determining the eligible shareholders (holding shares either in physical form or in dematerialized form) to cast their votes electronically between 27<sup>th</sup> September, 2021 (9:30 A.M. IST) to 29<sup>th</sup> September, 2021 (5:00 P.M. IST).

**Colinz Laboratories Limited** 

CIN NO- L24200MH1986PLC041128

Corp. Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 173: E-mail: colinzlabs@yahoo.com/colinzlabs@gmail.com

Mob.: + 91 9137392123 / + 91 9137389899

00 078. INDIA





101-103, REWA CHAMBERS 31, NEW MARINE LINES MUMBAI - 400 020. INDIA

**Q** 022-2200 5933 - 2200 5934

www.cavoras.com

office@cavoras.com cavoras@gmail.com

#### Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of COLINZ LABORATORIES LIMITED ('the Company') for the quarter ended 30<sup>th</sup> lune 2021 being submitted by the Company pursuant to the requirements of Regulation 33 of

Circular') and other accounting principles generally accepted in Impia. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410) "Review of Invention Elizabeth Statements Performed by the Indopendent Auditor of the Entity" issued by the Institute of Chartered Accordance of Indian

information deciding the second second of terms at Segue of the 1995 to 1995. Second s

For VORA & ASSOCIATES
CHARTERED ACCOUNTAN
ICALETER RES NOT 11161



UDIN: 21140371AAAAFM5886

reace: Moward bated: July 30, 2021



## COLINZ LABORATORIES LIMITED.

(CIN NO: L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

## UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2021

|        |   | IIm A.                      | lited                 |                       | "(Rs. In Lakhs       |
|--------|---|-----------------------------|-----------------------|-----------------------|----------------------|
| S. No. | Particulars   | Un-Audited<br>Quarter ended |                       | Audited               |                      |
|        |   |                             |                       | Quarter ended         | YEAR ENDE            |
|        |   | 30-Jun-21                   | 30-Jun-20             | 31-Mar-21             | 31-Mar-2             |
| 1      | (a)Revenue from Operation   | 185.04                      | 141.56                | 163.70                | 615.9                |
| 3      | (b) Othet Income  | 4.14                        | 3.22                  | 7.17                  | 19.1                 |
| 3      | Total Income from Operation   | 189.18                      | 144.78                | 170.87                | 635.0                |
| 4      | Expenses  |                             |                       |                       |                      |
|        | (a) Cost Of Material Consumed   | 16.66                       | 9.64                  | 7.88                  | 54.7                 |
|        | (b) Purchase of Stock in Trade (c) Change in Inventories Of Finished Goods and Work in Progress | 32.67                       | 22.64                 | 42.33                 | 116.7                |
|        | and Stock in Trade  | 10.55                       | 34.86                 | 1.26                  | 46.8                 |
|        | (d) Employee Benefit Expenses (e) Finance Cost (f) Depreciation & Amortisation Expenses         | 73.83<br>2.01<br>4.98       | 43.11<br>2.26<br>4.62 | 74.04<br>2.44<br>5.00 | 250.9<br>8.6<br>19.1 |
|        | (g) Other Expenses Total Expenses   | 37.28                       | 20.98                 | 31.98                 | 113.3                |
| 5      | Profit /(Loss) Before exceptional items and tax (3.4)   | 177.98                      | 138.11                | 164.93                | 610.4                |
|        | Exceptional items   | 11.20                       | 6.67                  | 5.94                  | 24.52                |
|        | Profit /(Loss) before tax (5-6)   | 11.20                       | 6.67                  | 5.94                  | 24.52                |
|        | Cax Expenses ( Provision for Taxation Current tax   | to entre the first          |                       |                       |                      |
|        | ) Current Tax<br>i) Deffered Tax  | 2.75                        | 1.25                  | 4.55                  | 8.30                 |
|        | ii) Tax for earlier years   | -                           |                       | (3.97)                | (3.97)               |
|        | v) MAT Credit of Earlier years  | -                           | -                     | (0.57)                | (0.57)               |
|        | Profit /(Loss) for the period from continuing operations(7-8)                                   | 8.45                        | 5.42                  | _5,93                 | 20,76                |

Profit /(Loss) for the period

Other Comprehensive Income ( Net of Tax)

A) Item that will not be reclassified to Profit or Loss Account

8.45 5.42 5.

20.75



CIN NO- 124200MH1996PTC7141128



# Colinz

### NOTES TO THE FINANCIAL RESULTS :-

1) The above financial results for the Quarter Ended 30.06.2021 have been prepared by the Company in accordance with Indian

Accounting Standards (Ind AS) prescribed under ecation 133 or the Companies Act, 2013 read with relevent Rules issued

thereunder and in item of Regulation 33 of SEBI (LODR) Regulation, 2015 (as amended) and were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 30th July, 2021.

- 2) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous figures have been regrouped/ rearranged, wherever necessary.

For and on behalf of the Board

COLINZ LABORATORIES LTD.

CIN NO: L24200MH1986PL0041128

MUMBAI.

30th July, 2021.

Dr. Mani L. S. (Din No: 00825886)

Director- Legal & Company Secretary



CIN NO- L24200MH1986PLC041128